Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Market Closed - London S.E. Other stock markets 09:05:16 13/05/2026 pm IST			5-day change	1st Jan Change
89.00 ^GBX	+4.09%		+25.35%	+53.45%

06/05	Avacta Therapeutics Presents New Comparisons Of Pre\|CISION Payload Release Versus Approved ADCs And AVA6207 Dual Payload Delivery	CI
22/04	Vaalco says remainder of 2026 to be "very profitable"	AN

Transcript : Avacta Group Plc - Special Call

Published on 04/10/2024 at 10:00 pm IST

S&P Capital IQ

Presenter Speech
Katie Pilbeam (Attendees)

Welcome to the Avacta Group webinar, which has been facilitated by Turner Pope Investments, which provides corporate broking services to listed companies, as

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Avacta Group Plc

06/05	Avacta Therapeutics Presents New Comparisons Of Pre\|CISION Payload Release Versus Approved ADCs And AVA6207 Dual Payload Delivery	CI
22/04	Vaalco says remainder of 2026 to be "very profitable"	AN
21/04	Avacta Therapeutics Presents Favorable Data for AVA6103 and Showcases Dual Payload pre\|CISION Platform At AACR 2026	CI
10/04	Somero Enterprises extends buyback to USD6.0 million	AN
09/04	Avacta hails "important milestones" in start of "transformative" year	AN
31/03	Avacta Therapeutics Announces First Patient Treated In Phase 1 Focus-01 Trial Of FAP-Exd	CI
27/03	Avacta Therapeutics Conditionally Raises GBP10 Million via Share Placing, Subscription	MT
27/03	Avacta raises GBP10 million in equity for clinical tests	AN
27/03	Avacta Therapeutics says placing & subscription represent 3.60% of issued share capital	RE
27/03	Avacta to Raise GBP10 Million via Equity Placing, Subscription	MT
26/03	Avacta Therapeutics proposed placing via accelerated bookbuild & subscription to raise about £10 million	RE
16/03	Avacta opens phase 1 trial for conjugate's efficacy regarding tumours	AN
16/03	Avacta Group announces phase 1 study opening for AVA6103	RE
24/02	Avacta hails new data supporting proprietary preCision platform	AN
24/02	Avacta Therapeutics Plans FAP-Exd's Clinical Trials After 'Favorable' Experimental Analysis	MT